Back to News
Market Impact: 0.3
Immunology Drugmaker Electra Opens Flat After Upsized US IPO
Source: Bloomberg
IPOs & SPACsHealthcare & BiotechCapital Markets
Electra Therapeutics raised $350 million in an upsized U.S. IPO, but its shares opened Friday at the IPO price, indicating muted immediate trading demand. The successful enlarged offering provides meaningful funding for the clinical-stage immunology drug developer, though the flat debut limits the near-term positive market signal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Anthropic releases amended IPO prospectus with third-quarter financials
- Anthropic to Spend $895 Billion in the Years Ahead
- Anthropic Revenue Nears $17 Billion as IPO Nears: Evening Briefing Americas
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Anthropic’s growth slowed and costs jumped in the third quarter, updated IPO filing shows
- Oracle Kicks Off $20 Billion Capital Raise